A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 Apr 2018 Planned End Date changed from 31 Oct 2022 to 31 Jan 2023.
- 24 Apr 2018 Planned primary completion date changed from 31 Oct 2018 to 31 Jan 2019.
- 01 Jun 2017 Planned number of patients changed from 130 to 240.